



PRESS RELEASE

AMOÉBA to gain access to the European market as soon as its solution is validated by ANSES

Chassieu, 29 February 2016 - AMOÉBA (FR0011051598 - AMEBA) producer of a biocide capable of eliminating waterborne bacterial risk announces that it will submit a request for provisional MA for all European countries - including France - as soon as ANSES (French Agency for Food, Environmental and Occupational Health & Safety) has validated the active principle in AMOÉBA's solution, which should take place in the first half of 2016.

Based on the assessment by ANSES, provisional MA will be requested from the competent authorities in European Union member states, and from ANSES in France.

This provisional MA will allow AMOÉBA to commercialise its product in Europe. AMOÉBA estimates that the provisional MA should be obtained within a month of submitting the request in France, and within 3 months of submission in member states.

At the time of making the requests for provisional MA, AMOÉBA has already constituted a commercial network in several European countries in the form of LOI with distributors based in Germany, Belgium, the Netherlands, Luxemburg and Italy.

"The companies who wish to benefit from AMOÉBA's solution are waiting for this provisional MA, which will give us the opportunity to immediately penetrate the European market and to rapidly settle our commercial status thanks to our distributors." comments **Fabrice PLASSON, President of AMOÉBA's Board of Directors.**

AMEBA
LISTED
EURONEXT

About AMOÉBA: Based in Chassieu - France, AMOÉBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector. Amoéba plans to commercialise its biocide in France from the first half of 2016 and in the rest of Europe from the end of 2016, provided market authorisation is awarded and the required notifications have been made⁽¹⁾. In a worldwide market for chemical biocides estimated to be worth 21 bn€⁽²⁾, AMOÉBA is today concentrating on the segment of industrial air-cooled towers (ACT) estimated to be worth 1.7 bn€⁽³⁾. Its disruptive technology complies with new regulations in terms of chemical emissions into the environment. AMOÉBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21 September last. For more information: www.amoeba-biocide.com.

(1): Commercialisation of the solution in France will only be possible once market authorisation has been acquired, the process for which could be completed at the end of 2016; however, due to the absence of risks to humans and the environment, its commercialisation would be possible before that date, from the time of delivery of a temporary authorisation which



could be awarded in the first half of 2016. The solution can be commercialised in European Union states in which the definitive French authorisation has been published on the condition that the countries concerned do not oppose its commercialisation (see section 6.9.1 of the basic document).

(2): Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(3): Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

Contacts:

Amoéba
Christine GENDROT LAURAIN
Head of Communication
+33(0)6 6210 8370
christine.laurain@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Financial communication
+33(0)1 5688 1111
ggasparetto@actifin.fr